Page 88 - 2019_04-Haematologica-web

B. Drexler et al.
release is regulated by circadian oscilla-
tions. Nature. 2008;452(7186):442-447.
7. Mendez-Ferrer S, Michurina TV, Ferraro F, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow
niche. Nature. 2010;466(7308):829-834.
8. Arranz L, Sanchez-Aguilera A, Martin- Perez D, et al. Neuropathy of haematopoi- etic stem cell niche is essential for myelo- proliferative neoplasms. Nature. 2014;
512(7512):78-81.
9. Khullar V, Amarenco G, Angulo JC, et al.
Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a ran- domised European-Australian phase 3 trial. Eur Urol. 2013;63(2):283-295.
10. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
11. Barosi G, Mesa R, Finazzi G, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood.
2013;121(23):4778-4781.
12. Tefferi A, Cervantes F, Mesa R, et al.
Revised response criteria for myelofibrosis: International Working Group- Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122(8):1395-1398.
13. Kralovics R, Teo SS, Li S, et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006;108(4):1377-1380.
14. Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123(14):2220-2228.
15. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European con- sensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128-1132.
16. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neo- plasms and acute leukemia. Blood.
2016;127(20):2391-2405.
17. Thiele J, Kvasnicka HM, Orazi A, et al.
Myeloprolifierative Neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer (IARC); 2017:585.
18. Kvasnicka HM, Beham-Schmid C, Bob R, et al. Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis - a consensus-based study. Histopathology. 2016;68(6):905-915.
19. Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a ran- domized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189(4):1388-1395.
20. Lofvenberg E, Wahlin A, Roos G, Ost A. Reversal of myelofibrosis by hydroxyurea. Eur J Haematol. 1990;44(1):33-38.
21. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353(1):33-45.
716
haematologica | 2019; 104(4)